Is Ardelyx Inc (ARDX) overvalued? · rev $333.6M
Ardelyx Inc (ARDX) is a biotechnology company listed on US.
This page asks whether Ardelyx Inc (ARDX) looks expensive on cached numbers — not a short thesis.
Latest reported ARDX revenue for 2024-12-31 was $333.6M. Net income was -$39.1M. Revenue was up 168.1% from 2023-12-31 to 2024-12-31. ARDX currently screens at market cap $1.37B.
ARDX currently screens at market cap $1.37B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ARDX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ARDX stock page for the full model, not this heading.
Not investment advice.